Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...
A newly approved combination of acalabrutinib plus venetoclax gives with newly diagnosed chronic lymphocytic leukemia (CLL) another chemotherapy-free option that is taken for a fixed period of time ...
The Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) tablets and capsules in combination with Venclexta (venetoclax) for adults with chronic lymphocytic leukemia (CLL) or ...
BEIJING, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today key clinical ...
Jaypirca showed superior PFS and lower discontinuation rates compared to standard treatments in CLL/SLL patients. Jaypirca reduced the risk of progression or death by 46% to 52% and had a favorable ...
6don MSN
AbbVie wins FDA nod for Venclexta-acalabrutinib combo in first-line chronic lymphocytic leukemia
AbbVie (ABBV) said Friday that the U.S. FDA has approved a supplemental new drug application for its combination regimen of Venclexta (venetoclax) and acalabrutinib to treat previously untreated ...
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA® (venetoclax) and ...
Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Prospective Patient Preference Study for BTKi Treatment Attributes in CLL and SLL” explored the factors influencing patient ...
AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic ...
Panelists discuss how, coming into ASH 2024, the largest unmet needs in the treatment and management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) include improving outcomes for ...
ATLANTA, Georgia — A novel investigational therapeutic agent appears to be an effective and safe treatment option for patients with chronic lymphocytic leukemia (CLL). According to 2 new studies ...
Expert Rev Hematol. 2013;6(4):441-449. The newest biological variables of prognostic relevance are useful for understanding the clinical heterogeneity of disease, however, their value at the time of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results